PRTG
Income statement / Annual
Last year (2024), Portage Biotech Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Portage Biotech Inc.'s net income was -$75.34 M.
See Portage Biotech Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$54.00 K
|
$1.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$54.00 K
|
-$1.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$12.54 M
|
$8.21 M
|
$6.77 M
|
$7.31 M
|
$4.11 M
|
$762.00 K
|
$561.00 K
|
$32.45 M
|
$4.58 M
|
$2.93 M
|
| General & Administrative Expenses |
$5.66 M
|
$8.36 M
|
$8.82 M
|
$5.13 M
|
$1.87 M
|
$1.87 M
|
$1.55 M
|
$2.56 M
|
$4.52 M
|
$1.30 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.66 M
|
$8.36 M
|
$8.82 M
|
$5.13 M
|
$1.87 M
|
$1.87 M
|
$1.55 M
|
$2.56 M
|
$4.52 M
|
$1.30 M
|
| Other Expenses |
$0.00
|
$1.00 K
|
$0.00
|
$0.00
|
$0.00
|
$134.00 K
|
$116.00 K
|
$484.00 K
|
$95.34 K
|
$91.00 K
|
| Operating Expenses |
$18.20 M
|
$16.58 M
|
$15.59 M
|
$12.44 M
|
$5.98 M
|
$2.76 M
|
$2.23 M
|
$35.49 M
|
$9.19 M
|
$4.32 M
|
| Cost And Expenses |
$18.25 M
|
$16.58 M
|
$15.59 M
|
$12.44 M
|
$5.98 M
|
$2.76 M
|
$2.23 M
|
$35.49 M
|
$9.19 M
|
$4.32 M
|
| Interest Income |
$274.00 K
|
$217.00 K
|
$43.00
|
$0.00
|
$11.00 K
|
$111.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$32.00 K
|
$9.00 K
|
$43.00 K
|
$177.00 K
|
$557.00 K
|
$88.00 K
|
$32.00 K
|
$552.42 K
|
$7.38 K
|
$20.04 K
|
| Depreciation & Amortization |
$54.00 K
|
$1.00 K
|
$15.59 M
|
$12.24 M
|
$5.98 M
|
$2.69 M
|
$168.00 K
|
$168.00 K
|
$9.19 M
|
$968.00
|
| EBITDA |
-$18.20 M |
-$15.78 M |
-$15.59 M |
-$14.19 M |
-$5.95 M |
-$650.00 K |
-$2.07 M |
-$35.33 M |
-$5.00 |
-$4.32 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$67.44 M
|
-$105.95 M
|
$771.00 K
|
-$2.45 M
|
-$531.00 K
|
-$830.00 K
|
$125.98 M
|
$34.86 M
|
-$7.38 K
|
-$115.84 K
|
| Income Before Tax |
-$85.70 M
|
-$122.52 M
|
-$14.82 M
|
-$14.89 M
|
-$6.53 M
|
-$3.59 M
|
$123.74 M
|
-$641.00 K
|
-$9.20 M
|
-$4.34 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$10.55 M
|
-$17.86 M
|
$4.35 M
|
$2.30 M
|
$740.00 K
|
-$217.00 K
|
$0.00
|
-$52.34 M
|
$0.00
|
-$1.22 M
|
| Net Income |
-$75.34 M
|
-$104.61 M
|
-$16.87 M
|
-$15.83 M
|
-$5.33 M
|
-$2.64 M
|
$123.74 M
|
$16.30 M
|
-$5.71 M
|
-$3.12 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.7 |
-6.49 |
-1.29 |
-1.35 |
-9.74 |
-0.55 |
924.14 |
6.42 |
-2.38 |
-1.61 |
| EPS Diluted |
-3.7 |
-6.49 |
-1.29 |
-1.35 |
-9.74 |
-0.55 |
917.8 |
120 |
-2.38 |
-1.61 |
| Weighted Average Shares Out |
$20.34 M
|
$16.12 M
|
$13.06 M
|
$11.73 M
|
$547.60 K
|
$4.82 M
|
$2.68 M
|
$2.54 M
|
$2.40 M
|
$1.93 M
|
| Weighted Average Shares Out Diluted |
$20.34 M
|
$16.12 M
|
$13.06 M
|
$11.73 M
|
$547.60 K
|
$4.82 M
|
$2.70 M
|
$2.72 M
|
$2.40 M
|
$1.93 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
